DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period

DSP President Masayo Tada Dainippon Sumitomo Pharma’s (DSP) sales during the April-September period climbed 1.5% from the same period last year to 181,396 million yen, helped by increased sales in North America of its atypical antipsychotic drug Latuda (lurasidone HCl)...read more